Page last updated: 2024-10-29

iotrolan and Spinal Cord Diseases

iotrolan has been researched along with Spinal Cord Diseases in 2 studies

iotrolan: nonionic, isotonic contrast medium designed for intrathecal use; RN given refers to cpd without isomeric designation; DL-3-117 refers to stereoisomer; structure given in first source

Spinal Cord Diseases: Pathologic conditions which feature SPINAL CORD damage or dysfunction, including disorders involving the meninges and perimeningeal spaces surrounding the spinal cord. Traumatic injuries, vascular diseases, infections, and inflammatory/autoimmune processes may affect the spinal cord.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19901 (50.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Palmers, Y1
Kuhn, FP1
Petersen, D1
De Greef, D1
Carella, A1
D'Aprile, P1
Medicamento, N1
Simone, F1
Paglialonga, P1

Trials

1 trial available for iotrolan and Spinal Cord Diseases

ArticleYear
Comparison in myelography between iodixanol 270 and 320 mgI/ml and iotrolan 300 mgI/ml: a multicentre, randomised, parallel-group, double-blind, phase III trial.
    European radiology, 2002, Volume: 12, Issue:3

    Topics: Contrast Media; Double-Blind Method; Female; Headache; Humans; Iodine; Male; Middle Aged; Myelograph

2002

Other Studies

1 other study available for iotrolan and Spinal Cord Diseases

ArticleYear
Iotrol: a new contrast medium for the subarachnoid space. Our clinical experience in myelography.
    Journal of neuroradiology = Journal de neuroradiologie, 1988, Volume: 15, Issue:4

    Topics: Adolescent; Adult; Aged; Contrast Media; Female; Humans; Iodobenzoates; Male; Middle Aged; Myelograp

1988